Compendium of Cancer Genome Aberrations

HAEM5:Volunteer Assignments and Opportunities: Difference between revisions

[unchecked revision][checked revision]
← Older edit
VisualWikitext
No edit summary
No edit summary
 
(142 intermediate revisions by 11 users not shown)
Line 1: Line 1:
Welcome!
Ian Welcome!
 
'''A new version of the Heme/Lymphoid book (5th edition) is in beta form on the WHO website with publication of a final form anticipated in 2024; we're aligning the related CCGA content to the new structure.'''
 
*For assignments, please see the "Author" column below (highlighted blue).
 
*If empty (no name is present), please volunteer to create content for that disease!
*If "PENDING" is present, the original author of that disease page is currently being contacted about revising the content.


*For assignments, please see the "Author" column below (3rd column from left). If no name is present, volunteer to create content!
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*To volunteer, please '''[[Mailto:CCGA@cancergenomics.org <u>Contact us</u>]]''' with your page of interest.
*Note - NEW (No Prior) means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content added.
*Note - "NEW (No Prior)" in the 4th edition columns means either the disease is a new entity in the 5th edition or the disease was present in the 4th edition without content previously added.
 
__TOC__


<br />
<br />
{| class="wikitable" style="margin:auto"
{| class="wikitable sortable" style="margin:auto"
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (4th Edition) Content</big>
|+<big>WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues (5th Edition) Content</big>
|-
|-
!Disease (5th Edition)!!Page Type!!Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)!!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Disease (5th Edition)!!Page Type!!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)!!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)!!Content Status (5th Edition)(Pending or Complete)!!Date Completed by Author (5th Edition)!!Associate Editor!!Date of Last Editor Review (5th Edition)!!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Correlated Prior Author (4th Edition)
Line 16: Line 25:
!Prior Notes (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)
|
====CHAPTER 2 (MYELOID PROLIFERATIONS AND NEOPLASMS)====
|
|
----<br />
----<br />
Line 22: Line 32:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease|| || || || || ||Fabiola Quintero-Rivera (FQR)|| ||
|[[HAEM5:Clonal haematopoiesis|Clonal haematopoiesis]]||Disease||Meenakshi Mehrotra
|4/8/24, email again in 9/29/25; Meenakshi confirmed om 9/30/25.
| ||Pending|| ||Fabiola Quintero-Rivera (FQR)|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 41: Line 65:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Clonal cytopenias of undetermined significance|Clonal cytopenias of undetermined significance]]||Disease||Zejuan Li
|10/3/2025
| ||Pending|| ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 48: Line 74:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myeloid leukaemia|Chronic myeloid leukaemia]]||Disease||J . Reid||9/29/25|| || || ||FQR|| ||
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Chronic Myeloid Leukemia (CML), BCR-ABL1 Positive
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Jack Reid, MD (University of California, Irvine)  Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 55: Line 81:
|
|
|-
|-
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic neutrophilic leukaemia|Chronic neutrophilic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Neutrophilic Leukemia (CNL)
|Chronic Neutrophilic Leukemia (CNL)
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
|Anamaria Munteanu, MD, Ph.D**, Harbor-UCLA Medical Center, Joseph J. Merlo Jr, MD. Ph.D**, Ashion Analytics, Fabiola Quintero-Rivera, University of California Irvine  <nowiki>**</nowiki>contributed equally
Line 62: Line 89:
|
|
|-
|-
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic eosinophilic leukaemia|Chronic eosinophilic leukaemia]]||Disease||Daynna Wolff
|10/14/25|| || || ||FQR|| ||
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chronic Eosinophilic Leukemia, Not Otherwise Specified
|Chelsea D. Kramish; Daynna J.Wolff
|Chelsea D. Kramish; Daynna J.Wolff
Line 69: Line 97:
|
|
|-
|-
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Polycythaemia vera|Polycythaemia vera]]||Disease||
| || || || ||FQR|| ||
|Polycythemia Vera (PV)
|Polycythemia Vera (PV)
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
|Gokce A. Toruner, MD, PhD  UT MD Anderson Cancer Center
Line 76: Line 105:
|
|
|-
|-
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Essential thrombocythaemia|Essential thrombocythaemia]]||Disease||Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|10/1/25|| ||Pending|| ||FQR|| ||
|Essential Thrombocythemia (ET)
|Essential Thrombocythemia (ET)
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
|Rebecca Smith, PhD, Director, Genetics Associates, Nashville, TN
Line 83: Line 113:
|
|
|-
|-
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Primary myelofibrosis|Primary myelofibrosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Primary Myelofibrosis (PMF)
|Primary Myelofibrosis (PMF)
|T. Niroshi Senaratne, UCLA
|T. Niroshi Senaratne, UCLA
Line 90: Line 121:
|
|
|-
|-
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' | || || || || ||FQR|| ||
|[[HAEM5:Juvenile myelomonocytic leukaemia|Juvenile myelomonocytic leukaemia]]||Disease|| '''Sarah Rapisardo, PhD, FACMG''' |PENDING
| || || || ||FQR|| ||
|Juvenile Myelomonocytic Leukemia (JMML)
|Juvenile Myelomonocytic Leukemia (JMML)
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
|<nowiki>Sarah Rapisardo, PhD, FACMG | Assistant Professor, Pathology</nowiki>
Line 101: Line 133:
|FQR has emailed SR several times, last 4/20/22
|FQR has emailed SR several times, last 4/20/22
|-
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Myeloproliferative neoplasm, NOS|Myeloproliferative neoplasm, NOS]]||Disease||PENDING
| || || || ||FQR|| ||
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Myeloproliferative Neoplasm (MPN), Unclassifiable
|Thomas Lee, MD, PhD, University of California, Los Angeles
|Thomas Lee, MD, PhD, University of California, Los Angeles
Line 108: Line 157:
|
|
|-
|-
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Cutaneous mastocytosis|Cutaneous mastocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Cutaneous Mastocytosis
|Cutaneous Mastocytosis
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
|S. Shawn Liu, MD, PhD and Thuy Phung, MD, PhD
Line 115: Line 165:
|
|
|-
|-
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Systemic mastocytosis|Systemic mastocytosis]]||Disease||PENDING|| || || || ||FQR|| ||
|Systemic Mastocytosis
|Systemic Mastocytosis
|'''Abdullah Osme, MD,''' University Hospitals Cleveland Medical Center, Case Western Reserve University  '''Shashi Shetty, Ph.D. FACMG, FCCMG,''' University Hospitals Cleveland Medical Center, Case Western Reserve University
|Abdullah Osme, MD, University Hospitals Cleveland Medical Center, Case Western Reserve University  Shashi Shetty, Ph.D. FACMG, FCCMG, University Hospitals Cleveland Medical Center, Case Western Reserve University
|Complete
|Complete
|
|
|
|
|-
|-
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Mast cell sarcoma|Mast cell sarcoma]]||Disease||PENDING
| || || || ||FQR|| ||
|Mast Cell Sarcoma
|Mast Cell Sarcoma
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
|Jordan Lowery, MD and Thuy Phung, MD, PhD  Department of Pathology, University of South Alabama, Mobile, AL
Line 129: Line 180:
|
|
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and 5q deletion|Myelodysplastic neoplasm with low blasts and 5q deletion]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Myelodysplastic Syndrome (MDS) with Isolated del(5q)
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
|Xiaolin Hu, Ph.D; Teresa Smolarek, Ph.D, FACMG
Line 136: Line 188:
|
|
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with low blasts and SF3B1 mutation|Myelodysplastic neoplasm with low blasts and SF3B1 mutation]]||Disease||
| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 143: Line 196:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?)|| || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with biallelic TP53 inactivation|Myelodysplastic neoplasm with biallelic TP53 inactivation]]||Disease||Eric McGinnis (assigned to new 5th edition page - FQR is this reviewed?) YES fqr 9/29/25|| || || || ||FQR|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 164: Line 217:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic neoplasm with increased blasts|Myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Myelodysplastic Syndrome (MDS) with Excess Blasts
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 171: Line 225:
|
|
|-
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease|| || || || || ||FQR|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with low blasts|Childhood myelodysplastic neoplasm with low blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 178: Line 249:
|
|
|-
|-
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Childhood myelodysplastic neoplasm with increased blasts|Childhood myelodysplastic neoplasm with increased blasts]]||Disease||PENDING
| || || || ||FQR|| ||
|Refractory Cytopenia of Childhood
|Refractory Cytopenia of Childhood
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
|Xiaoli Du, Ph.D; Teresa A. Smolarek, Ph.D, FACMG  Division of Human Genetics, Cincinnati Children's Hospital Medical Center
Line 185: Line 257:
|
|
|-
|-
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Chronic myelomonocytic leukaemia|Chronic myelomonocytic leukaemia]]||Disease||PENDING
| || || || ||FQR|| ||
|Chronic Myelomonocytic Leukemia (CMML)
|Chronic Myelomonocytic Leukemia (CMML)
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 192: Line 265:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with neutrophilia|Myelodysplastic/myeloproliferative neoplasm with neutrophilia]]||Disease||PENDING
| || || || ||FQR|| ||
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Atypical Chronic Myeloid Leukemia (aCML), BCR-ABL1 Negative
|Linsheng Zhang, MD, PhD
|Linsheng Zhang, MD, PhD
Line 199: Line 273:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis|Myelodysplastic/myeloproliferative neoplasm with SF3B1 mutation and thrombocytosis]]||Disease||PENDING
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Myelodysplastic/Myeloproliferative Neoplasms with Ring Sideroblasts and Thrombocytosis (MDS/MPN-RS-T)
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
|Anamaria Munteanu, MD, Ph.D, Harbor-UCLA Medical Center, Fabiola Quintero-Rivera, University of California Irvine
Line 206: Line 281:
|
|
|-
|-
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease|| || || || || ||FQR|| ||
|[[HAEM5:Myelodysplastic/myeloproliferative neoplasm, NOS|Myelodysplastic/myeloproliferative neoplasm, NOS]]||Disease||
| || || || ||FQR|| ||
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN), Unclassifiable
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
|Ruth MacKinnon PhD  Victorian Cancer Cytogenetics Service  Melbourne, Australia
Line 215: Line 291:
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|[[HAEM5:Acute promyelocytic leukaemia with PML::RARA fusion|Acute promyelocytic leukaemia with PML::RARA fusion]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|Pending
|
|
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|
|
|
|
|Acute Promyelocytic Leukemia (APL) with PML-RARA
|Jennelle Hodge (JH)/ Malini Sathanoori (MS)
|
|
|Acute Promyelocytic Leukemia (APL) with PML-RARA
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|Yiming Zhong, Ph.D., Megan Piazza, Ph.D., and Shashi Shetty, Ph.D.
|Complete
|Complete
Line 231: Line 308:
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion|Acute myeloid leukaemia with RUNX1::RUNX1T1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 247: Line 325:
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|[[HAEM5:Acute myeloid leukaemia with CBFB::MYH11 fusion|Acute myeloid leukaemia with CBFB::MYH11 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 263: Line 342:
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|[[HAEM5:Acute myeloid leukaemia with DEK::NUP214 fusion|Acute myeloid leukaemia with DEK::NUP214 fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 276: Line 355:
|02/24/2021-MS (re-review)
|02/24/2021-MS (re-review)
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|[[HAEM5:Acute myeloid leukaemia with RBM15::MRTFA fusion|Acute myeloid leukaemia with RBM15::MRTFA fusion]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Complete
|
|
|
|JH_MS
|JH_MS
Line 295: Line 390:
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Acute myeloid leukaemia with BCR::ABL1 fusion|Acute myeloid leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 311: Line 407:
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with KMT2A rearrangement|Acute myeloid leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 327: Line 424:
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with MECOM rearrangement|Acute myeloid leukaemia with MECOM rearrangement]]
|Disease
|Disease
|Gordana Raca MD PhD,
|9/8/25
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 343: Line 440:
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|[[HAEM5:Acute myeloid leukaemia with NUP98 rearrangement|Acute myeloid leukaemia with NUP98 rearrangement]]
|Disease
|Disease
|Eric McGinnis, MD
|Eric McGinnis, MD;
Fatma Al-Bulushi (trannee)
|12/20/23
|12/20/23
|
|
|
|Pending
|
|
|JH_MS
|JH_MS
Line 366: Line 464:
|JH_MS
|JH_MS
|
|
|
|emailed request on 7/16/24. No response as of 9/7/25.
Prior author: Xinjie Xu, PhD, FACMG
 
Open to new author
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Acute Myeloid Leukemia (AML) with Mutated NPM1
|Xinjie Xu, PhD, FACMG
|Xinjie Xu, PhD, FACMG
|Complete
|Complete
|
|
|Add WHO reference
|Add WHO reference<br />
|-
|-
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|[[HAEM5:Acute myeloid leukaemia with CEBPA mutation|Acute myeloid leukaemia with CEBPA mutation]]
|Disease
|Disease
|
|Xinxiu Xu (trainee);
|
Malini Sathanoori, Ph.D.
|4/15/25
|
|
|
|
Line 398: Line 500:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Acute Myeloid Leukemia (AML) with Myelodysplasia-Related Changes
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
|Fei Yang, MD, FACMG  <br> Oregon Health & Science University
Line 430: Line 532:
|JH_MS
|JH_MS
|
|
|
|Prior author: Celeste Eno, PhD
 
Open to new author
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Acute Myeloid Leukemia (AML) with Minimal Differentiation
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
|Celeste Eno, PhD, Cedars Sinai Medical Center, Los Angeles,  Fabiola Quintero-Rivera, MD, FACMG, University of California Irvine
Line 436: Line 540:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|[[HAEM5:Acute myeloid leukaemia without maturation|Acute myeloid leukaemia without maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 455: Line 575:
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|[[HAEM5:Acute myeloid leukaemia with maturation|Acute myeloid leukaemia with maturation]]
|Disease
|Disease
|Jennelle C. Hodge, PhD
|
|
|
|
|
|Pending
|
|
|
|JH_MS
|JH_MS
Line 471: Line 591:
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|[[HAEM5:Acute basophilic leukaemia|Acute basophilic leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 494: Line 614:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Myelomonocytic Leukemia
|Acute Myelomonocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 510: Line 630:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Monoblastic and Monocytic Leukemia
|Acute Monoblastic and Monocytic Leukemia
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 519: Line 639:
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|[[HAEM5:Acute erythroid leukaemia|Acute erythroid leukaemia]]
|Disease
|Disease
|Ashwini Yenamandra PhD FACMG
|5/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 542: Line 662:
|JH_MS
|JH_MS
|
|
|
|emailed request on 5/1/24 and reminder on 10/28/24. No response as of 9/7/25
|Acute Megakaryoblastic Leukemia (AMKL)
|Acute Megakaryoblastic Leukemia (AMKL)
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
|Fei Yang, MD, FACMG <br> Oregon Health & Science University
Line 551: Line 671:
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|[[HAEM5:Myeloid sarcoma|Myeloid sarcoma]]
|Disease
|Disease
|Yalda Naeini
|6/11/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 586: Line 706:
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|[[HAEM5:Myeloid neoplasm post cytotoxic therapy|Myeloid neoplasm post cytotoxic therapy]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 599: Line 720:
|
|
|Check reference format
|Check reference format
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|[[HAEM5:Myeloid neoplasms associated with germline predisposition|Myeloid neoplasms associated with germline predisposition]]
|Disease
|Disease
|Malini Sathanoori, Ph.D.
|12/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 625: Line 762:
|JH_MS
|JH_MS
|
|
|
|Prior author:
Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|MERGE 3 PAGES --> Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome  +  Transient Abnormal Myelopoiesis (TAM) Associated with Down Syndrome + Myeloid Leukemia Associated with Down Syndrome
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
|Linda D Cooley, MD, MBA, Children's Mercy Hospital, Kansas City, MO
Line 634: Line 772:
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRA rearrangement|Myeloid/lymphoid neoplasm with PDGFRA rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 650: Line 788:
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with PDGFRB rearrangement|Myeloid/lymphoid neoplasm with PDGFRB rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 666: Line 804:
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|[[HAEM5:Myeloid/lymphoid neoplasm with FGFR1 rearrangement|Myeloid/lymphoid neoplasm with FGFR1 rearrangement]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 717: Line 855:
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|[[HAEM5:Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion|Myeloid/lymphoid neoplasm with ETV6::ABL1 fusion]]
|Disease
|Disease
|Mayuri Shende (trainee);
Scott Turner (mentor)<br />
|9/22/24
|
|
|Pending
|
|
|
|FQR
|
|
|FQR
|
|
|
|
Line 733: Line 872:
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|[[HAEM5:Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes|Myeloid/lymphoid neoplasms with other tyrosine kinase fusion genes]]
|Disease
|Disease
|Rolando Garcia
|2/7/2025
|
|
|
|Pending
|
|
|
|
|FQR
|FQR
Line 749: Line 888:
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|[[HAEM5:Mixed-phenotype acute leukaemia with BCR::ABL1 fusion|Mixed-phenotype acute leukaemia with BCR::ABL1 fusion]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 762: Line 901:
|
|
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|[[HAEM5:Mixed-phenotype acute leukaemia with KMT2A rearrangement|Mixed-phenotype acute leukaemia with KMT2A rearrangement]]
|Disease
|Disease
|Tracy Tucker, PhD, FCCMG
|4/6/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 797: Line 952:
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|[[HAEM5:Mixed-phenotype acute leukaemia, B/myeloid|Mixed-phenotype acute leukaemia, B/myeloid]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 813: Line 969:
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|[[HAEM5:Mixed-phenotype acute leukaemia, T/myeloid|Mixed-phenotype acute leukaemia, T/myeloid]]
|Disease
|Disease
|
|PENDING
|
|
|
|
Line 820: Line 976:
|JH_MS
|JH_MS
|
|
|
|emailed 5/1/24
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Mixed Phenotype Acute Leukemia (MPAL), T/Myeloid, Not Otherwise Specified
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
|Narsis Attar, MD, PhD, Fabiola Quintero-Rivera, MD University of California, Irvine
Line 829: Line 985:
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|[[HAEM5:Mixed-phenotype acute leukaemia, rare types|Mixed-phenotype acute leukaemia, rare types]]
|Disease
|Disease
|Daynna Wolff, PhD
|5/9/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 861: Line 1,017:
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|[[HAEM5:Acute undifferentiated leukaemia|Acute undifferentiated leukaemia]]
|Disease
|Disease
|Rabail Aslam, MD (trainee);
Shashi Shetty, Ph.D.
|7/1/24
|
|
|
|Pending
|
|
|
|
|JH_MS
|JH_MS
Line 875: Line 1,032:
|Check reference format
|Check reference format
|-
|-
|CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
====CHAPTER 3 (HISTIOCYTIC/DENRITIC CELL NEOPLASMS)====
|
|
----<br />
----<br />
Line 881: Line 1,055:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
|[[HAEM5:Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm|Mature plasmacytoid dendritic cell proliferation associated with myeloid neoplasm]]
Line 911: Line 1,097:
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|[[HAEM5:Blastic plasmacytoid dendritic cell neoplasm|Blastic plasmacytoid dendritic cell neoplasm]]
|Disease
|Disease
|
|Daynna Wolff
|
|5/3/2025
|
|8/3/2025
|
|Pending
|
|
|GC
|GC
Line 938: Line 1,124:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
Line 954: Line 1,140:
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Dr Malaika Perchard BSci(MedSci), MBBS, FRACP, FRCPA, (Paediatric Haematologist) Pathology Queensland
|Complete
|Complete
|5/19/2022<br />
|5/19/2022 Emailed 5/6/2025, no reply<br />
|Date completed by author: 04/28/2022
|Date completed by author: 04/28/2022
|-
|-
Line 975: Line 1,161:
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|[[HAEM5:Interdigitating dendritic cell sarcoma|Interdigitating dendritic cell sarcoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025
|
|Pending
|
|
|GC
|GC
Line 991: Line 1,177:
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|[[HAEM5:Juvenile xanthogranuloma|Juvenile xanthogranuloma]]
|Disease
|Disease
|
|Mayuri Shende (trainee);
|
Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|GC
Line 1,007: Line 1,194:
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|[[HAEM5:Erdheim-Chester disease|Erdheim-Chester disease]]
|Disease
|Disease
|
|Mayuri Shende (trainee);
|
Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|GC
Line 1,023: Line 1,211:
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|[[HAEM5:Rosai-Dorfman Disease|Rosai-Dorfman Disease]]
|Disease
|Disease
|
|Mayuri Shende (trainee);
|
Scott Turner (mentor)<br />
|
|9/22/24
|
|12/22/24 Emailed 9/4/2025 to remind
|Pending
|
|
|GC
|GC
Line 1,067: Line 1,256:
|Complete
|Complete
|10/01/2021
|10/01/2021
|Date completed by author: 10/01/2021
|Date completed by author: 10/01/2021. Emailed both authors 5/1/2025, no reply.
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|
====CHAPTER 4 (B-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|
|
----<br />
----<br />
Line 1,075: Line 1,281:
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|[[HAEM5:Reactive B-cell rich lymphoid proliferations that can mimic lymphoma|Reactive B-cell rich lymphoid proliferations that can mimic lymphoma]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,106: Line 1,323:
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|[[HAEM5:IgG4-related disease|IgG4-related disease]]
|Disease
|Disease
|
|Muhammad Zulfiqar, MD
|
|7/4/2025
|
|10/4/2025 Emailed 9/4/2025 to remind
|
|Pending
|
|
|GC
|GC
Line 1,165: Line 1,382:
|Sudha Arumugam, MD
|Sudha Arumugam, MD
|Complete
|Complete
|01/24/2022
|01/24/2022. Emailed 5/1/2025, no response
|Date completed by author: 01/24/2022
|Date completed by author: 01/24/2022
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma|B-lymphoblastic leukaemia/lymphoma]]
|Disease
|Disease
|To be covered in B-ALL, NOS
|
|
|
|
|
|
|
|
|
|Sumi Kitahara (SK)
|Holli Drendel (HD)
|
|
|
|
Line 1,186: Line 1,419:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy|B-lymphoblastic leukaemia/lymphoma with high hyperdiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|
|SK
|
|HD
|
|
|
|
Line 1,202: Line 1,435:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with hypodiploidy|B-lymphoblastic leukaemia/lymphoma with hypodiploidy]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|
|
|
|
|Complete (pending review by SK)
|
|
|
|SK
|
|HD
|
|
|
|
Line 1,218: Line 1,451:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with iAMP21|B-lymphoblastic leukaemia/lymphoma with iAMP21]]
|Disease
|Disease
|Holli authoring - Complete? Looks like needs more editing of tables
|Holli Drendel, PhD
|
|Nov 11/2025
|
|
|Pending
|
|
|
|SK
|HD
|
|
|
|
Line 1,234: Line 1,467:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1 fusion]]
|Disease
|Disease
|Karin Miller, MD
|10/9/2025
|12/5/2025
|
|
|
|
|
|SK
|
|
|HD
|
|
|
|
Line 1,250: Line 1,483:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features|B-lymphoblastic leukaemia/lymphoma with BCR::ABL1-like features]]
|Disease
|Disease
|
|Mark G. Evans, MD
|
|10/1/2025
|
|11/17/2025
|
|Complete (pending review by SK)
|
|11/8/2025
|HD
|SK
|
|Pending
|
|
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
|B-Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like
Line 1,266: Line 1,499:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement|B lymphoblastic leukaemia/lymphoma with KMT2A rearrangement]]
|Disease
|Disease
|Gokce A. Toruner, MD, PhD
|10/9/2025
|11/5/2025
|Pending
|
|
|
|SK
|
|
|
|HD
|
|
|
|
Line 1,282: Line 1,515:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion|B lymphoblastic leukaemia/lymphoma with ETV6::RUNX1 fusion]]
|Disease
|Disease
|Gokce A. Toruner, MD, PhD
|10/8/2025
|12/1/2025
|Pending
|
|
|
|SK
|
|
|
|HD
|
|
|
|
Line 1,298: Line 1,531:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features|B-lymphoblastic leukaemia/lymphoma with ETV6::RUNX1-like features]]
|Disease
|Disease
|Lei Zhang, PhD
Michelle Fan (trainee)
|10/10/2025
|12/22/2025
|Pending
|
|
|
|SK
|
|
|
|HD
|
|
|
|
Line 1,314: Line 1,548:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion|B lymphoblastic leukaemia/lymphoma with TCF3::PBX1 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|
|SK
|
|
|HD
|
|
|
|
Line 1,330: Line 1,564:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion|B lymphoblastic leukaemia/lymphoma with IGH::IL3 fusion]]
|Disease
|Disease
|Miguel Gonzalez Mancera, MD
|10/1/2025
|
|
|Pending
|
|
|
|SK
|
|
|HD
|
|
|
|
Line 1,346: Line 1,580:
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|[[HAEM5:B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion|B lymphoblastic leukaemia/lymphoma with TCF3::HLF fusion]]
|Disease
|Disease
|
|Aiko Otsubo, PhD
|
|10/10/2025
|
|11/24/2025
|
|Complete (pending SK review)
|
|11/11/2025
|HD
|SK
|
|Pending
|
|
|NEW (No Prior)
|NEW (No Prior)
Line 1,362: Line 1,596:
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations|B-lymphoblastic leukaemia/lymphoma with other defined genetic alterations]]
|Disease
|Disease
|Lei Zhang, PhD
|10/10/2025
|12/22/2025
|Pending
|
|
|
|SK
|
|
|
|HD
|
|
|
|
Line 1,377: Line 1,611:
|-
|-
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|[[HAEM5:B-lymphoblastic leukaemia/lymphoma, NOS|B-lymphoblastic leukaemia/lymphoma, NOS]]
|Disease
|Disease  
|Karin Miller, MD
|10/9/2025
|11/24/2025
|Pending
|
|SK
|
|
|
|
Line 1,383: Line 1,623:
|
|
|
|
|HD
|
|
|
|
|NEW (No Prior)
|-
|NEW (No Prior)
!Disease (5th Edition)
|NEW (No Prior)
!Page Type
|NEW (No Prior)
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|NEW (No Prior)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|RESOLVE 4th edition ALL-Related NON-WHO entities content
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4 + B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6 + B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements + B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions + B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19) + B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|B-Lymphoblastic Leukemia/Lymphoma with t(4;14)(q35.2;q32); IGH/DUX4
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;12)(p13;p13); PAX5/ETV6
 
 
B-Lymphoblastic Leukemia/Lymphoma with ZNF384 Rearrangements
 
 
B-Lymphoblastic Leukemia/Lymphoma with IKZF1 Deletions
 
 
B-Lymphoblastic Leukemia/Lymphoma with TCF3 Rearrangements - Excluding t(1;19) and t(12;19)
 
 
B-Lymphoblastic Leukemia/Lymphoma with dic(9;20)(p13;q11)
|ISSUE- FIX
|ISSUE- FIX


Line 1,411: Line 1,676:
|
|
|-
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease|| || || || || ||Shivani Golem (SG)
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Monoclonal B-cell lymphocytosis|Monoclonal B-cell lymphocytosis]]||Disease||PENDING; Shashirekha Shetty
| ||9/4/2025 sent E-mail reminder|| || ||Shivani Golem (SG)
| ||
| ||
|Monoclonal B-cell Lymphocytosis
|Monoclonal B-cell Lymphocytosis
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|Tsigab Bahta Hagos (trainee) / Shashirekha Shetty
|PENDING
|PENDING, 4/30/2024
|
|
|Assigned 12/19/2022 with completion date of 1/19/2023
|Assigned 12/19/2022 with completion date of 1/19/2023
|-
|-
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa
|[[HAEM5:Chronic lymphocytic leukaemia/small lymphocytic lymphoma|Chronic lymphocytic leukaemia/small lymphocytic lymphoma]]||Disease||Jaime Nagy, PhD, University of Iowa,


Renee Eigsti, MD, Pathology Services of Kalamazoo
Renee Eigsti, MD, Pathology Services of Kalamazoo,


Honey Reddi, PhD, Belay Diagnostics
Honey Reddi, PhD, Belay Diagnostics
| || ||Complete (Shivani, please confirm)|| ||SG|| ||
| || ||Complete|| ||SG|| ||
|Already converted to 5th edition
|Already converted to 5th edition
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
|Jamie Nagy, PhD, University of Iowa  Honey Reddi, PhD
Line 1,431: Line 1,713:
|
|
|-
|-
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Hairy cell leukaemia|Hairy cell leukaemia]]||Disease||Michael Lack, MD, KUMC (trainee);
Shivani Golem
|7/16/24||9/4/2025 sent E-mail reminder||PENDING|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia
|Hairy Cell Leukemia
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
|Complete
|Pending WHO 5th e. July 2024
|
|
|
|
|-
|-
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Splenic marginal zone lymphoma|Splenic marginal zone lymphoma]]||Disease||Madhu Pantrangi
|4/15/25|| ||9/4/2025 sent E-mail reminder|| ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Marginal Zone Lymphoma
|Splenic Marginal Zone Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,445: Line 1,730:
|
|
|-
|-
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease|| || || || || ||SG|| ||
|[[HAEM5:Splenic diffuse red pulp small B-cell lymphoma|Splenic diffuse red pulp small B-cell lymphoma]]||Disease||
| || || || ||SG|| ||Need new author to update latest content. Prior author cannot update the page.
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Splenic Diffuse Red Pulp Small B-cell Lymphoma
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,461: Line 1,747:
|SG
|SG
|
|
|
|Need new author to update latest content. Prior author cannot update the page.
|Hairy Cell Leukemia Variant
|Hairy Cell Leukemia Variant
|Snehal Patel, MD, PhD
|Snehal Patel, MD, PhD
Line 1,472: Line 1,758:
|
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|SG
|
|
|
|Email sent to request to update 2024
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1) Lymphoplasmacytic Lymphoma + (2) Waldenstrom Macroglobulinemia
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
|(1 and 2) Kapitolina Semenova, MD, Jack Reid, MD, Fabiola Quintero-Rivera, MD  Departments of Pathology, Laboratory Medicine, and Pediatrics, Division of Genetic and Genomic Medicine, University of California, Irvine (UCI)
Line 1,488: Line 1,774:
|
|
|
|
|
|Sent e-mail to prev authors no reply
|
|
|
|
|SG
|SG
|
|
|
|Email sent to request to update 2024
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue (MALT Lymphoma)
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
|Whayoung Lee, MD (trainee), Fabiola Quintero-Rivera, MD, FACMG*
Line 1,504: Line 1,790:
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|[[HAEM5:Primary cutaneous marginal zone lymphoma|Primary cutaneous marginal zone lymphoma]]
|Disease
|Disease
|Molly Walkenhorst
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,513: Line 1,799:
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|Molly Walkenhorst, DO and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|[[HAEM5:Nodal marginal zone lymphoma|Nodal marginal zone lymphoma]]
|Disease
|Disease
|Andrew Ly
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,543: Line 1,845:
|SG
|SG
|
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric Nodal Marginal Zone Lymphoma
|Paediatric Nodal Marginal Zone Lymphoma
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|* Kathleen M. Schieffer, PhD * Ruthann Pfau, PhD
|Complete
|Complete; Need new author to update latest content. Primary author cannot update the page.
|11/11/2020
|11/11/2020
|
|
Line 1,554: Line 1,856:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,570: Line 1,872:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|Pending
|Pending
|
|
Line 1,584: Line 1,886:
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|[[HAEM5:Paediatric-type follicular lymphoma|Paediatric-type follicular lymphoma]]
|Disease
|Disease
|Rachel D. Burnside, PhD, MBA, FACMGG
|
|
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside 7/17/2024
|
|
|
|
|
|SG
|SG
|
|
|
|Need new author to update latest content. Prior authors cannot update the page.
|Paediatric-Type Follicular Lymphoma
|Paediatric-Type Follicular Lymphoma
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|*Kathleen M. Schieffer, PhD *Ruthann Pfau, PhD, FACMG
|Complete
|Complete; Need new author to update latest content. Primary author  cannot update the page.
|8/16/2020
|8/16/2020
|
|
Line 1,602: Line 1,904:
|Rachel D. Burnside, PhD, MBA, FACMGG
|Rachel D. Burnside, PhD, MBA, FACMGG
|7/28/2023
|7/28/2023
|
|9/4/2025 sent email reminder; Last E-mail to Dr. Burnside no reply 7/17/
|Pending
|Pending
|
|
Line 1,616: Line 1,918:
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|[[HAEM5:Primary cutaneous follicle centre lymphoma|Primary cutaneous follicle centre lymphoma]]
|Disease
|Disease
|Linlin Gao
|
|
|
|9/4/2025 Sent E-mail to remind
|
|
|
|
|
Line 1,648: Line 1,950:
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|[[HAEM5:Mantle cell lymphoma|Mantle cell lymphoma]]
|Disease
|Disease
|PENDING
|
|
|
|9/4/2025 set E-mail reminder
|
|
|
|
|
Line 1,657: Line 1,959:
|
|
|Mantle Cell Lymphoma
|Mantle Cell Lymphoma
|* Mahsa Khanlari, MD * Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Mahsa Khanlari, MD and  Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas
|Pending
|Pending
|
|
Line 1,664: Line 1,966:
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|[[HAEM5:Leukaemic non-nodal mantle cell lymphoma|Leukaemic non-nodal mantle cell lymphoma]]
|Disease
|Disease
|Farhan Sami
|
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
Line 1,673: Line 1,975:
|
|
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|[[HAEM5:Transformations of indolent B-cell lymphomas|Transformations of indolent B-cell lymphomas]]
|Disease
|Disease
|Farhan Sami
|
|
|9/4/2025 sent E-mail reminder
|
|
|
|
|
|SG
|
|SG
|
|
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|Include content on chronic myelomonocytic leukemia in transformation and refractory anaemia with excess blasts in transformation
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|Farhan Sami, MD and Shivani Golem, PhD, FACMG
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Diffuse large B-cell lymphoma, NOS|Diffuse large B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Diffuse Large B-cell Lymphoma, Not Otherwise Specified
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
|Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center
Line 1,708: Line 2,027:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements|Diffuse large B-cell lymphoma / high grade B-cell lymphoma with MYC and BCL2 rearrangements]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025||8/6/2025 Emailed 9/4/2025 to remind|| || ||GC|| ||
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|High-Grade B-cell Lymphoma with MYC and BCL2 and/or BCL6 Rearrangements
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland
Line 1,715: Line 2,035:
|
|
|-
|-
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:ALK-positive large B-cell lymphoma|ALK-positive large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||
|ALK-Positive Large B-cell Lymphoma
|ALK-Positive Large B-cell Lymphoma
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Manando Nakasaki, MD, PhD (University of California, Irvine)  Fabiola Quintero-Rivera, MD, FACMG (University of California, Irvine)
|Pending
|
|
|
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|Nakasaki Manando removed March 2022 due to no progress/contact 1y. Added Nakasaki Manando back n 8/29/22 based on newer email communication (Jennelle's note). 2021 template added. FQR emailed Manando on 4/12/23
|-
|-
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Large B-cell lymphoma with IRF4 rearrangement|Large B-cell lymphoma with IRF4 rearrangement]]||Disease||
| || || || ||GC|| ||
|Large B-cell Lymphoma with IRF4 Rearrangement
|Large B-cell Lymphoma with IRF4 Rearrangement
|Afia Hasnain, MBBS, PhD
|Afia Hasnain, MBBS, PhD
|Complete
|Complete
|5/26/2021
|5/26/2021. Emailed 5/7//2025, no reply
|
|
|-
|-
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:High grade B-cell lymphoma with 11q aberrations|High grade B-cell lymphoma with 11q aberrations]]||Disease||
| || || || ||GC|| ||
|Burkitt-Like Lymphoma with 11q Aberration
|Burkitt-Like Lymphoma with 11q Aberration
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Lauren Shealy, MD, Medical University of South Carolina  Daynna Wolff, PhD, Medical University of South Carolina
|Comlete
|Complete
|27/01/2022
|27/01/2022 Emailed 5/7//2025, no reply
|
|
|-
|-
Line 1,743: Line 2,066:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:EBV-positive diffuse large B-cell lymphoma|EBV-positive diffuse large B-cell lymphoma]]||Disease||Fnu Monika (trainee);
Andrew Siref as mentor
|3/22/24|| ||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,757: Line 2,082:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Fibrin-associated large B-cell lymphoma|Fibrin-associated large B-cell lymphoma]]||Disease||
| || || || ||GC|| ||Note: previously a subset DLBCL assoc with chronic inflam
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|Originally called Fibrin-Associated Diffuse Large B-cell Lymphoma; NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,771: Line 2,113:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Plasmablastic lymphoma|Plasmablastic lymphoma]]||Disease||
| || || || ||GC|| ||
|Plasmablastic Lymphoma
|Plasmablastic Lymphoma
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
|Mark Evans, MD (University of California, Irvine)  Fabiola Quintero-Rivera, MD (University of California, Irvine)
Line 1,778: Line 2,121:
|
|
|-
|-
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Primary large B-cell lymphoma of immune-privileged sites|Primary large B-cell lymphoma of immune-privileged sites]]||Disease||Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|6/28/2025
|9/28/2025 Emailed 9/4/2025 to remind.|| || ||GC|| ||
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Diffuse Large B-cell Lymphoma, Not Otherwise Specified + (2) Primary Diffuse Large B-cell Lymphoma of the CNS
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
|(1) Ashwini Yenamandra, PhD FACMG, Vanderbilt University Medical Center + (2) Laveniya Satgunaseelan, FRCPA, Department of Neuropathology, Royal Prince Alfred Hospital
Line 1,792: Line 2,137:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:Intravascular large B-cell lymphoma|Intravascular large B-cell lymphoma]]||Disease||Kate Berry, MBBS, BBus (Hons), Pathology Queensland
|5/6/2025
|8/6/2025 Emailed 9/4/2025 to remind
| || ||GC|| ||
|Intravascular Large B-cell Lymphoma
|Intravascular Large B-cell Lymphoma
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
|Kate Berry, MBBS, BBus (Hons), Pathology Queensland, Greg Corboy
Line 1,813: Line 2,161:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease|| || || || || ||GC|| ||
|[[HAEM5:High-grade B-cell lymphoma, NOS|High-grade B-cell lymphoma, NOS]]||Disease||
| || || || ||GC|| ||
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|High-Grade B-cell Lymphoma, Not Otherwise Specified (NOS)
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Aiko Otsubo, PhD, Indiana University, Holli Drendel
|Complete
|Complete
|16/11/2021
|16/11/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
|Burkitt lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Burkitt lymphoma|Burkitt lymphoma]]||Disease||
| || || || ||GC|| ||
|Burkitt Lymphoma
|Burkitt Lymphoma
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Becky Leung, MBBS (Hons), BSc, Pathology Queensland
|Complete
|Complete
|28/06/2021
|28/06/2021 Emailed 5/6/2025, no reply
|
|
|-
|-
|Primary effusion lymphoma||Disease|| || || || || ||GC|| ||
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary effusion lymphoma|Primary effusion lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,834: Line 2,200:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive diffuse large B-cell lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:KSHV/HHV8-positive diffuse large B-cell lymphoma|KSHV/HHV8-positive diffuse large B-cell lymphoma]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,841: Line 2,207:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|KSHV/HHV8-positive germinotropic lymphoproliferative disorder||Disease|| || || || || ||GC|| ||
|[[HAEM5:KSHV/HHV8-positive germinotropic lymphoproliferative disorder|KSHV/HHV8-positive germinotropic lymphoproliferative disorder]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,848: Line 2,214:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hyperplasias arising in immune deficiency/dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others")|| || || || ||GC|| ||
|[[HAEM5:Hyperplasias arising in immune deficiency/dysregulation|Hyperplasias arising in immune deficiency/dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing non-destructive post-transplant lymphoproliferative disorders, among others"). "Non-Destructive Post-Transplant Lymphoproliferative Disorders" was a HAME4 page but no content.  What are "among others" from HAEM4 to see if we need to pull prior content into 5th edition page.|| || || || ||GC|| ||
|
|
|
|
Line 1,855: Line 2,221:
|
|
|-
|-
|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
|[[HAEM5:Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation|Polymorphic lymphoproliferative disorders arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "This page was converted to the new template on 2023-12-07. The original page can be found at [[HAEM4:Polymorphic Post-Transplant Lymphoproliferative Disorders]].
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
Note: encompassing polymorphic PTLD, other iatrogenic immunodef-assoc lympho disorders, among others)"
| || || || ||GC|| ||
| || || || ||GC|| ||
Line 1,864: Line 2,230:
|
|
|-
|-
|EBV-positive mucocutaneous ulcer||Disease|| || || || || ||GC|| ||
|[[HAEM5:EBV-positive mucocutaneous ulcer|EBV-positive mucocutaneous ulcer]]||Disease|| || || || || ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,871: Line 2,237:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Lymphomas arising in immune deficiency / dysregulation||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|[[HAEM5:Lymphomas arising in immune deficiency / dysregulation|Lymphomas arising in immune deficiency / dysregulation]]||Disease||FIX ISSUE! (on 5th edition page instructions say "encompassing monomorphic PTLD, classic HL PTLD, lymphomas assoc with HIV infection, among others"|| || || || ||GC|| ||
|
|
|
|
Line 1,878: Line 2,244:
|
|
|-
|-
|Inborn error of immunity-associated lymphoid proliferations and lymphomas||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]")|| || || || ||GC|| ||
|[[HAEM5:Inborn error of immunity-associated lymphoid proliferations and lymphomas|Inborn error of immunity-associated lymphoid proliferations and lymphomas]]||Disease||FIX ISSUE! (on 5th edition page instructions say "Editor said this overview page is a match. [Immunodeficiency-Associated Lymphoproliferative Disorders] [Lymphoproliferative diseases associated with primary immune disorders]") - last link name above is not a known page in haem4 or haem5.|| || || || ||GC|| ||
|
|
|
|
Line 1,885: Line 2,251:
|
|
|-
|-
|Classic Hodgkin lymphoma||Disease|| || || || ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|[[HAEM5:Classic Hodgkin lymphoma|Classic Hodgkin lymphoma]]||Disease||Xiaolin Hu
|GC|| ||
|5/7/2025
|8/7/2025 Reminder email sent 9/4/2025|| ||
|GC|| ||Note: author needs to merge Nodular Sclerosis Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Mixed Cellularity Classic Hodgkin Lymphoma, Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Lymphocyte-Rich Classic Hodgkin Lymphoma + (2) Nodular Sclerosis Classic Hodgkin Lymphoma + (3) Mixed Cellularity Classic Hodgkin Lymphoma + (4) Lymphocyte-Depleted Classic Hodgkin Lymphoma
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
|(1) Patricia V. Hernandez, M.D., Washington University School of Medicine and Holli Drendel + (2) Xiaolin Hu, PhD, Sema4 OpCo Inc. + (3 and 4) Patricia V. Hernandez
Line 1,893: Line 2,261:
|
|
|-
|-
|Nodular lymphocyte predominant Hodgkin lymphoma||Disease|| || || || || ||GC|| ||
|[[HAEM5:Nodular lymphocyte predominant Hodgkin lymphoma|Nodular lymphocyte predominant Hodgkin lymphoma]]||Disease||Muhammad Zulfiqar, MD
|7/4/2025
|10/4/2025 Reminder email sent 9/4/2025||Pending|| ||GC|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,900: Line 2,270:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Cold agglutinin disease
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Cold agglutinin disease|Cold agglutinin disease]]
|Disease
|
|
|
|
|
Line 1,916: Line 2,302:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|[[HAEM5:IgM monoclonal gammopathy of undetermined significance|IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,923: Line 2,309:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Non-IgM monoclonal gammopathy of undetermined significance||Disease|| || || || || ||SG|| ||
|[[HAEM5:Non-IgM monoclonal gammopathy of undetermined significance|Non-IgM monoclonal gammopathy of undetermined significance]]||Disease|| || || || || ||SG|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
Line 1,930: Line 2,316:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Monoclonal gammopathy of renal significance||Disease|| || || || || ||SG
|[[HAEM5:Monoclonal gammopathy of renal significance|Monoclonal gammopathy of renal significance]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,938: Line 2,324:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Immunoglobulin-related (AL) amyloidosis||Disease|| || || || || ||SG
|[[HAEM5:Immunoglobulin-related (AL) amyloidosis|Immunoglobulin-related (AL) amyloidosis]]||Disease||
| || || || ||SG
| ||
| ||
|Primary Amyloidosis
|Primary Amyloidosis
Line 1,946: Line 2,333:
|
|
|-
|-
|Monoclonal immunoglobulin deposition disease||Disease|| || || || || ||SG
|[[HAEM5:Monoclonal immunoglobulin deposition disease|Monoclonal immunoglobulin deposition disease]]||Disease||
| || || || ||SG
| ||
| ||
|Light Chain and Heavy Chain Deposition Disease
|Light Chain and Heavy Chain Deposition Disease
Line 1,954: Line 2,342:
|
|
|-
|-
|Mu heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Mu heavy chain disease|Mu heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,962: Line 2,350:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Gamma heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Gamma heavy chain disease|Gamma heavy chain disease]]||Disease||
| || || || ||SG
| ||
| ||
|Gamma Heavy Chain Disease
|Gamma Heavy Chain Disease
Line 1,970: Line 2,359:
|
|
|-
|-
|Alpha heavy chain disease||Disease|| || || || || ||SG
|[[HAEM5:Alpha heavy chain disease|Alpha heavy chain disease]]||Disease|| || || || || ||SG
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
Line 1,978: Line 2,367:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasmacytoma||Disease|| || || || ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|[[HAEM5:Plasmacytoma|Plasmacytoma]]||Disease||
| || || ||
|SG
|SG
| ||
| ||author needs to include Solitary plasmacytoma of bone, Extraosseous plasmacytoma (extramedullary) (v4 page did not have content on ccga)
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior) - no content on version 4 page "Plasmacytoma' originally assigned to Zhenya Tang
|NEW (No Prior)
|NEW (No Prior)
Line 1,987: Line 2,377:
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Plasma cell myeloma / multiple myeloma||Disease|| || || || ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page||SG
|[[HAEM5:Plasma cell myeloma / multiple myeloma|Plasma cell myeloma / multiple myeloma]]||Disease||Huan Mo;
| ||
Zhenya Tang
|4/14/25||7/14/25
9/4/2025 Sent E-mail reminder to Dr. Tang
|Pending|| ||SG
| ||Note: author needs to include Plasma_Cell_Myeloma_Variants content in this page
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Plasma Cell Myeloma + (2) Plasma Cell Myeloma Variants
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
|(1) Huan Mo, MD, MS and Zhenya Tang, MD, PhD  The University Of Texas MD Anderson Cancer Center, Department of Hematopathology, Houston, Texas + (2) Fariborz Rashid-Kolvear, PhD, FACMG, FCCMG
Line 1,995: Line 2,389:
|
|
|-
|-
|Plasma cell neoplasms with associated paraneoplastic syndrome||Disease|| || || || ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|[[HAEM5:Plasma cell neoplasms with associated paraneoplastic syndrome|Plasma cell neoplasms with associated paraneoplastic syndrome]]||Disease||PENDING
| ||9/4/2025 E-mail sent to Dr. Senaratne
| ||
|SG
|SG
| ||
| ||Note: author needs to include POEMS, TEMPI, and look for AESOP content
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1) POEMS Syndrome + (2) TEMPI Syndrome
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
|(1 and 2) Sohini Anand, MBBS  Tharanga Niroshini Senaratne, PhD
Line 2,004: Line 2,400:
|
|
|-
|-
|CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)
|Disease (5th Edition)
|
|Page Type
----<br />
|Author (5th Edition) (Note: please indicate trainees in parenthesis)
|
|Date Assigned to Author (5th Edition)
----<br />
|Target Completion Date (5th Edition)
|
|Content Status (5th Edition) (Pending or Complete)
|
|Date Completed by Author (5th Edition)
|
|Associate Editor
|
|Date of Last Editor Review (5th Edition)
|
|Notes (5th Edition)
|
|Correlated Prior Disease Name (4th Edition)
|
|Correlated Prior Author (4th Edition)
|
|Prior Content Status (4th Edition) (Pending or Complete)
|
|Prior Date of Last Editor Review (4th Edition)
|
|Prior Notes (4th Edition)
|
|-
|
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
| colspan="15" |
====CHAPTER 5 (T-CELL AND NK-CELL LYMPHOID PROLIFERATIONS AND LYMPHOMAS)====
|-
|-
|Kikuchi-Fujimoto disease||Disease|| || || || || ||Sumi Kitahara (SK)
|[[HAEM5:Kikuchi-Fujimoto disease|Kikuchi-Fujimoto disease]]||Disease|| Sumire Kitahara, MD|| || || '''Complete'''|| 11/6/2025||Sumi Kitahara (SK)
| ||
| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Autoimmune lymphoproliferative syndrome|Autoimmune lymphoproliferative syndrome]]||Disease||Aviv Oren, MD (trainee);
Karin Miller, MD
|3/25/2024
| ||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Indolent T-lymphoblastic proliferation|Indolent T-lymphoblastic proliferation]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-lymphoblastic leukaemia / lymphoma, NOS|T-lymphoblastic leukaemia / lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Early T-precursor lymphoblastic leukaemia / lymphoma|Early T-precursor lymphoblastic leukaemia / lymphoma]]
|Disease
|Fei Yang, MD
|
|
|
|
|
|
|
|
|
|SK
|-
|Autoimmune lymphoproliferative syndrome||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|Early T-Cell Precursor Lymphoblastic Leukemia
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|Pending
|
|
|
|
|-
|-
|Indolent T-lymphoblastic proliferation||Disease|| || || || || ||SK|| ||
|[[HAEM5:T-prolymphocytic leukaemia|T-prolymphocytic leukaemia]]
|Disease
|Parastou Tizro, MD;
Celeste Eno, PhD; Sumire Kitahara, MD
|9/23/2025
|11/4/2025
|'''Complete'''
|11/4/2025
|SK
|11/6/2025
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:T-large granular lymphocytic leukaemia|T-large granular lymphocytic leukaemia]]||Disease||Nicolas LaScala (trainee);
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|Pending
| ||SK|| ||
|T-cell Large Granular Lymphocytic Leukemia
|Michelle Don, MD, MS
|Pending
|
|
|
|
|-
|[[HAEM5:NK-large granular lymphocytic leukaemia|NK-large granular lymphocytic leukaemia]]||Disease||Hailee St. Louis (trainee);
Michelle Don, MD, MS
|9/24/2025
|12/9/2025
|'''Complete'''
| 12/17/2025||SK|| 1/6/2026||
|Chronic Lymphoproliferative Disorder of NK Cells
|Michelle Don, MD
|Pending
|
|
|
|
|-
|-
|T-lymphoblastic leukaemia / lymphoma, NOS||Disease|| || || || || ||HD|| ||
|[[HAEM5:Adult T-cell leukaemia/lymphoma|Adult T-cell leukaemia/lymphoma]]||Disease||Sumire Kitahara, MD
|
|9/23/2025
|11/30/2025
|Pending
| ||SK|| ||
|Adult T-cell Leukemia/Lymphoma
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|?Pending
|
|
|
|
|-
|[[HAEM5:Sezary syndrome|Sezary syndrome]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed
| || ||SK|| ||
|Sézary Syndrome
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|Pending
|
|
|
|
|-
|-
|Early T-precursor lymphoblastic leukaemia / lymphoma
|[[HAEM5:Aggressive NK-cell leukaemia|Aggressive NK-cell leukaemia]]||Disease||Shashirekha Shetty, PhD
|Disease
|10/15/2025||1/19/2026
|
|Pending
|
| ||SK|| ||
|
|Aggressive NK-cell Leukemia
|
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|
|?Pending
|HD
|
|
|
|Fei Yang, MD, FACMG, Kaiser Permanente Northwest
|
|
|
|
|
|-
|-
|T-prolymphocytic leukaemia
!Disease (5th Edition)
|Disease
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
|
!Target Completion Date (5th Edition)
|
!Content Status (5th Edition)(Pending or Complete)
|
!Date Completed by Author (5th Edition)
|SK
!Associate Editor
|
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder]]||Disease||Ian King, PhD
|1/6/2026
| 2/3/2026||
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder]]||Disease||Ahmed Eladely (trainee);
 
Andrew Siref, MD
|10/14/2025
|11/24/2025
|'''Complete'''
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Mycosis fungoides|Mycosis fungoides]]||Disease||Daynna J. Wolff, PhD
|3/22/2024
|follow-up needed|| || ||SK|| ||
|Mycosis Fungoides
|Jane Scribner, MD and Daynna J. Wolff, PhD
|Pending
|
|
|
|
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024
|follow-up needed
|
|
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma]]||Disease||Rabail Aslam, MD (fellow);
Shashirekha Shetty, PhD
|7/1/2024||follow-up needed
|
|
| ||SK|| ||
|Primary Cutaneous Anaplastic Large Cell Lymphoma
|Theresa Spivey, MD, Shashirekha Shetty, PhD
|Pending
|
|
|
|
|-
|-
|T-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
|[[HAEM5:Subcutaneous panniculitis-like T-cell lymphoma|Subcutaneous panniculitis-like T-cell lymphoma]]||Disease||Ian King, PhD
|
Katelyn Swanson, DO (trainee)
|*Michelle Don, MD, MS
|11/19/2025
|
|12/19/2025
|
|'''Complete'''
|
| 1/6/2026||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Primary cutaneous gamma/delta T-cell lymphoma|Primary cutaneous gamma/delta T-cell lymphoma]]||Disease||Mahzad Azimpouran (trainee);
Sumire Kitahara, MD
|6/30/2024
|11/9/2025
|Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|NK-large granular lymphocytic leukaemia||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma]]||Disease||Ahmed Eladely (trainee);
|
 
|Michelle Don, MD
Andrew Siref, MD
|
|10/14/2025||11/24/2025
|
|'''Complete'''
|
| 12/29/2025||SK|| 1/6/2026||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Adult T-cell leukaemia/lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Primary cutaneous peripheral T-cell lymphoma, NOS|Primary cutaneous peripheral T-cell lymphoma, NOS]]||Disease|| || || || || ||SK|| ||
|
|NEW (No Prior)
|Prasad R. Kopparapu, PhD and Ferrin C. Wheeler, PhD, FACMG  Vanderbilt University Medical Center
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Indolent T-cell lymphoma of the gastrointestinal tract|Indolent T-cell lymphoma of the gastrointestinal tract]]||Disease||
| || || || ||SK|| ||
|Indolent T-cell Lymphoproliferative Disorder of the Gastrointestinal Tract
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|
|
|-
|[[HAEM5:Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Enteropathy-associated T-cell lymphoma|Enteropathy-associated T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Enteropathy-Associated T-cell Lymphoma
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|Complete
|1/21/2021
|
|
|-
|-
|Sezary syndrome||Disease|| || || || || ||SK|| ||
|[[HAEM5:Monomorphic epitheliotropic intestinal T-cell lymphoma|Monomorphic epitheliotropic intestinal T-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
Andrew Siref, MD
|10/14/2025
| ||Pending|| ||SK|| ||
|Monomorphic Epitheliotropic Intestinal T-cell Lymphoma
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|Pending
|
|
|Madison E. Hannay, DO, Medical University of South Carolina  Tingting Barrett, MD, Medical University of South Carolina  Daynna J. Wolff, PhD, Medical University of South Carolina
|
|
|-
|[[HAEM5:Intestinal T-cell lymphoma, NOS|Intestinal T-cell lymphoma, NOS]]||Disease||
| || || || ||SK|| ||
|Intestinal T-cell Lymphoma, Not Otherwise Specified (NOS)
|Derick Okwan MD, PhD (Stanford)  Sumire Kitahara MD (Cedars-Sinai)
|Complete
|9/26/2022
|
|
|-
|[[HAEM5:Hepatosplenic T-cell lymphoma|Hepatosplenic T-cell lymphoma]]||Disease||Forough Sargolzaeiaval (trainee);
Michelle Don, MD, MS
|9/24/2025
|11/9/2025
|'''Complete'''
|12/17/2025
|SK||1/6/2026||
|Hepatosplenic T-cell Lymphoma
|Michelle Don, MD, MS
|Complete
|1/21/2021
|
|
|-
|-
|Aggressive NK-cell leukaemia||Disease|| || || || || ||SK|| ||
|[[HAEM5:ALK-positive anaplastic large cell lymphoma|ALK-positive anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
 
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Positive
|Miguel Gonzalez Mancera, MD
 
Sumire Kitahara, MD
 
Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|Shanelle De Lancy, MD, Shashirekha Shetty, PhD
|-
|[[HAEM5:ALK-negative anaplastic large cell lymphoma|ALK-negative anaplastic large cell lymphoma]]||Disease||Miguel Gonzalez Mancera, MD (trainee);
Sumire Kitahara, MD
|6/6/24|| ||
| ||SK|| ||
|Anaplastic Large Cell Lymphoma, ALK-Negative
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|Complete
|09/23/2022
|
|
|-
|[[HAEM5:Breast implant-associated anaplastic large cell lymphoma|Breast implant-associated anaplastic large cell lymphoma]]||Disease||Lynne Abruzzo, MD, PhD
|9/22/2025
|1/1/2026
|Pending|| ||SK|| ||
|Breast Implant-Associated Anaplastic Large Cell Lymphoma
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|Pending
|
|
|
|
|-
|-
|Primary cutaneous CD4-positive small or medium T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
!Disease (5th Edition)
|
!Page Type
|
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
|
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|[[HAEM5:Nodal TFH cell lymphoma, angioimmunoblastic-type|Nodal TFH cell lymphoma, angioimmunoblastic-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|follow-up needed
| || ||SK|| ||prior authors not available
|Angioimmunoblastic T-cell Lymphoma
|Sara Akhavanfard, M.D., Ph.D. and Ruthann Pfau, Ph.D., FACMG
|Pending
|
|
|
|
|-
|-
|Primary cutaneous acral CD8-positive T-cell lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|[[HAEM5:Nodal TFH cell lymphoma, follicular-type|Nodal TFH cell lymphoma, follicular-type]]||Disease||Rachel Burnside, PhD||7/28/2023
|
|follow-up needed
|
| || ||SK|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Nodal TFH cell lymphoma, NOS|Nodal TFH cell lymphoma, NOS]]||Disease||
| || || || ||SK|| ||
|Nodal Peripheral T-cell Lymphoma with T Follicular Helper Phenotype
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|Pending
|
|
|
|
|-
|-
|Mycosis fungoides||Disease|| || || || || ||SK|| ||
|[[HAEM5:Peripheral T-cell lymphoma, NOS|Peripheral T-cell lymphoma, NOS]]||Disease||Bo Hong, MD
|
|10/14/2025
|Jane Scribner, MD and Daynna J. Wolff, PhD
|12/3/2025
|
|Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Lymphomatoid papulosis||Disease|| || || || || ||SK|| ||
|[[HAEM5:EBV-positive nodal T- and NK-cell lymphoma|EBV-positive nodal T- and NK-cell lymphoma]]||Disease||Fnu Monika, MBBS (trainee);
|
Andrew Siref, MD
|
|10/14/2025|| ||Pending|| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Primary cutaneous CD30-positive T-cell lymphoproliferative disorder: Primary cutaneous anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Extranodal NK/T-cell lymphoma|Extranodal NK/T-cell lymphoma]]||Disease||Maryam Mehdiopour Dalivand (trainee); Ian King, PhD
|
|1/6/2026
|Theresa Spivey, MD, Shashirekha Shetty, PhD
| 2/3/2026||Pending
|
| ||SK|| ||
|
|NEW (No Prior)
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Subcutaneous panniculitis-like T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Severe mosquito bite allergy|Severe mosquito bite allergy]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Hydroa vacciniforme lymphoproliferative disorder|Hydroa vacciniforme lymphoproliferative disorder]]||Disease|| || || || || ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic chronic active EBV disease|Systemic chronic active EBV disease]]||Disease||Karin Miller, MD
|3/25/2024
| 11/17/2025||Pending
| ||SK|| ||
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|[[HAEM5:Systemic EBV-positive T-cell lymphoma of childhood|Systemic EBV-positive T-cell lymphoma of childhood]]||Disease||Karin Miller, MD
|3/25/2024
| 11/17/2025||Pending
| ||SK|| ||prior authors not available
|Systemic EBV-Positive T-cell Lymphoma of Childhood
|Lisa A. Lansdon, PhD and Linda D. Cooley, MD, MBA
|Complete
|11/21/2021
|
|
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|
|
====CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)====
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Primary cutaneous gamma/delta T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
----<br />
|
|
|-
----<br />
|Primary cutaneous CD8-positive aggressive epidermotropic cytotoxic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Primary cutaneous peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|[[HAEM5:Follicular dendritic cell sarcoma|Follicular dendritic cell sarcoma]]
|Disease
|
|
|
|
Line 2,180: Line 2,937:
|
|
|
|
|-
|GC
|Indolent T-cell lymphoma of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|
|
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|
|
|Follicular Dendritic Cell Sarcoma
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|?Pending
|
|
|
|
|-
|-
|Indolent NK-cell lymphoproliferative disorder of the gastrointestinal tract||Disease|| || || || || ||SK|| ||
|[[HAEM5:EBV-positive inflammatory follicular dendritic cell sarcoma|EBV-positive inflammatory follicular dendritic cell sarcoma]]
|Disease
|
|
|
|
Line 2,194: Line 2,953:
|
|
|
|
|-
|GC
|Enteropathy-associated T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|*Derick Okwan-Duodu, MD, PhD *Sumire Kitahara, MD
|
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Monomorphic epitheliotropic intestinal T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Fibroblastic reticular cell tumour|Fibroblastic reticular cell tumour]]
|
|Disease
|Derick Okwan-Duodu MD, PhD; Sumire Kitahara, MD
|
|
|
|
|
|
|-
|Intestinal T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|Derick Okwan MD, PhD (Stanford Medicine, CA)  Sumire Kitahara MD (Cedars-Sinai, CA)
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Hepatosplenic T-cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Intranodal palisaded myofibroblastoma|Intranodal palisaded myofibroblastoma]]
|Disease
|
|
|*Michelle Don, MD, MS
|
|
|
|
|-
|ALK-positive anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|ALK-negative anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|[[HAEM5:Littoral cell angioma|Littoral cell angioma]]
|
|Disease
|Miguel Gonzalez Mancera, MD  Sumire Kitahara, MD  Cedars-Sinai, Los Angeles, CA
|
|
|
|
|
|
|-
|Breast implant-associated anaplastic large cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
|Derick Okwan-Duodu, MD, PhD; Sumire Kitahara, MD  Cedars-Sinai Medical Center
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal TFH cell lymphoma, angioimmunoblastic-type||Disease|| || || || || ||SK|| ||
|[[HAEM5:Splenic hamartoma|Splenic hamartoma]]
|Disease
|
|
|* Sara Akhavanfard, M.D., Ph.D. * Ruthann Pfau, Ph.D., FACMG
|
|
|
|
|-
|Nodal TFH cell lymphoma, follicular-type||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Nodal TFH cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|[[HAEM5:Sclerosing angiomatoid nodular transformation (SANT) of spleen|Sclerosing angiomatoid nodular transformation (SANT) of spleen]]
|Disease
|
|
|Hans Magne Hamnvåg, MD  Kamran Mirza, MD, PhD
|
|
|
|
|-
|Peripheral T-cell lymphoma, NOS||Disease|| || || || || ||SK|| ||
|
|
|
|
|
|
|GC
|
|
|
|
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
!Disease (5th Edition)
!Page Type
!<span style="color:#0070C0">Author (5th Edition) (Note: please indicate trainees in parentheses)
!Date Assigned to Author (5th Edition)
!Target Completion Date (5th Edition)
!Content Status (5th Edition)(Pending or Complete)
!Date Completed by Author (5th Edition)
!Associate Editor
!Date of Last Editor Review (5th Edition)
!Notes (5th Edition)
!Correlated Prior Disease Name (4th Edition)
!Correlated Prior Author (4th Edition)
!Prior Content Status (4th Edition)(Pending or Complete)
!Prior Date of Last Editor Review (4th Edition)
!Prior Notes (4th Edition)
|-
|-
|EBV-positive nodal T- and NK-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
====CHAPTER 7 (GENETIC TUMOUR SYNDROMES)====
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Extranodal NK/T-cell lymphoma||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
|-
----<br />
|Severe mosquito bite allergy||Disease|| || || || || ||SK|| ||
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|
|
----<br />
|-
|-
|Hydroa vacciniforme lymphoproliferative disorder||Disease|| || || || || ||SK|| ||
|[[HAEM5:Fanconi anaemia|Fanconi anaemia]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A||N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Systemic chronic active EBV disease||Disease|| || || || || ||SK|| ||
|[[HAEM5:Bloom syndrome|Bloom syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|
|N/A
|N/A
|N/A
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|NEW (No Prior)
|-
|-
|Systemic EBV-positive T-cell lymphoma of childhood||Disease|| || || || || ||SK|| ||
|[[HAEM5:Ataxia-telangiectasia syndrome|Ataxia-telangiectasia syndrome]]||Disease||[[GTS5:Volunteer Assignments and Opportunities|See GTS5 volunteer sheet for authorship status]]||N/A||N/A||N/A||N/A||N/A||N/A||N/A
|
|NEW (No Prior)
|*Lisa A. Lansdon, PhD & Linda D. Cooley, MD, MBA
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|
|NEW (No Prior)
|-
|-
|CHAPTER 6 (STROMA-DERIVED NEOPLASMS OF LYMPHOID TISSUES)
|[[HAEM5:RASopathies|RASopathies]]||Disease|| || || || || ||NA|| ||
|
|NEW (No Prior)
----<br />
|NEW (No Prior)
|
|NEW (No Prior)
----<br />
|NEW (No Prior)
|
|NEW (No Prior)
|
|
|
|
|
|
|
|
|
|
|
|-
|Follicular dendritic cell sarcoma
|Disease
|
|
|
|
|
|GC
|
|
|
|Anna Heimes Dillon, MD and Shivani Golem, PhD, FACMG
|
|
|
|-
|EBV-positive inflammatory follicular dendritic cell sarcoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Fibroblastic reticular cell tumour
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Intranodal palisaded myofibroblastoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Littoral cell angioma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Splenic hamartoma
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|Sclerosing angiomatoid nodular transformation (SANT) of spleen
|Disease
|
|
|
|
|
|GC
|
|
|
|
|
|
|
|-
|CHAPTER 7 (GENETIC TUMOUR SYNDROMES)
|
----<br />
|
----<br />
|
|
|
|
|
|
|
|
|
|
|
|
|-
|Fanconi anaemia||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Bloom syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|Ataxia-telangiectasia syndrome||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|-
|RASopathies||Disease|| || || || || ||NA|| ||
|
|
|
|
|
|}
|}
Retrieved from "https://test.ccga.io/index.php/HAEM5:Volunteer_Assignments_and_Opportunities"